Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
We outline common circumstances where index funds may be preferable to ETFs, including buy-and-hold strategies and simplicity.
25,141 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Taiwan Semiconductor Manufacturing Co. reports a 36% quarterly sales increase, with June revenue surging as memory eq...
A softer-than-expected June producer price index has traders pricing in earlier rate cuts, sending crypto markets hig...
Nvidia could be headed toward a $300 stock price as AI demand, margins, and strategic bets align. This article breaks...
Uniswap community votes on v4 fees and Robinhood Chain expansion, potentially boosting the UNI burn as part of the UN...
Palantir Technologies has had a wild ride. If you’re wondering should palantir technologies stock be bought under $14...
Visa and Mastercard dominate the way billions of purchases are paid for worldwide. This article explains why their ne...
Tech stocks energized trading as Snowflake surged on a major Amazon deal and solid results. This cautious optimism co...
A Columbia psychology expert argues that the don’t yourself workplace, actually, mindset may impede effective leaders...
SoFi Technologies reports strong Q1 2026 results, highlighting revenue growth and expanding membership, while the sto...
A 15-year view of Alphabet shows how a modest initial bet could compound amid AI and cloud expansion, delivering a po...
A two-year income lookback can trigger Medicare IRMAA surcharges that cut into Social Security checks. This is a time...